1. Bakkila BF, Basu S, Lipska KJ. Catastrophic Spending On Insulin In The United States, 2017-18. Health Aff . 2022;41(7):1053-1060.
2. Sayed BA, Finegold K, Anders Olsen T, et al. Insulin Affordability and the Inflation Reduction Act: Medicare Beneficiary Savings by State and Demographics. ASPE Office of Health Policy. Published January 24, 2023. Accessed March 21, 2023. https://aspe.hhs.gov/sites/default/files/documents/bd5568fa0e8a59c2225b2e0b93d5ae5b/aspe-insulin-affordibility-datapoint.pdf
3. Glied S, Zhu B. Not So Sweet: Insulin Affordability over Time. Commonwealth Fund Issue Brief, September. Published September 2020. Accessed March 21, 2023. https://www.commonwealthfund.org/sites/default/files/2020-09/Glied_not_so_sweet_insulin_affordability_ib.pdf.
4. Hopkins JS. Diabetes Drug Giant Sanofi Cuts Insulin Prices by Up to 78%. WSJ Online. Published March 16, 2023. Accessed March 21, 2023. https://www.wsj.com/articles/diabetes-drug-giant-sanofi-cuts-insulin-prices-by-up-to-78-e9d7ada3
5. Li M, Yuan J, Lu K. Estimates of Insulin Out-of-Pocket Cap-Associated Prescription Satisfaction, Adherence, and Affordability Among Medicare Beneficiaries. JAMA Netw Open. 2023;6(1):e2251208.